SLC22A6 and chronic kidney disease: Considering the wide array of substrates transported by OAT1, the competition between drugs, toxins, and gut-derived metabolites at the site of the transporter could also lead to drug-metabolite interactions (DMI) —especially in patients with CKD, who are likely to be taking multiple drugs to treat symptoms associated with comorbidities.